Home > Keryx Biopharmaceuticals Salary

Keryx Biopharmaceuticals Salary

  • 82
  • 48
  • 12
Keryx Biopharmaceuticals average salary is $117,000, median salary is $117,000 with a salary range from $117,000 to $117,000.
Keryx Biopharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Keryx Biopharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
117,000
Average
117,000
Median
117,000
High
117,000
Total 1 Keryx Biopharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Senior Scientist, Analytical Services 117,000-117,000 Boston, MA, 02101 2017 Keryx Biopharmaceuticals Senior Scientist, Analytical Services Salaries (1)
Keryx Biopharmaceuticals Boston, MA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Keryx Biopharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Keryx Biopharmaceuticals Jobs
See more Keryx Biopharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Keryx Biopharmaceutica... Information
  • Keryx Biopharmaceuticals, Inc
  • Industry: BioTech/Drugs
  • City: Newyork, NY
  • Keryx Biopharmaceuticals is a drug discovery company focused on developinginnovative therapies through its proprietary technologies for the treatment ofcritical medical conditions including cancer and diabetes. Keryx isdeveloping KRX-101 (sulodexide), a novel treatment for diabetic nephropathy.In August 2001, KRX-101 received "Fast-Track" designation from the UnitedStates Food and Drug Administration and Keryx is preparing to initiate Phase 3clinical trials for this drug pursuant to a Subpart-H clinical developmentplan. Subpart H allows for the use of surrogate endpoints in pivotal Phase 3trials to support NDA approval, with confirmatory studies completedpost-approval. Keryx believes that this approach could greatly reduce thedevelopment time to